Candesic in the new PharmaTimes
29 August 2024A change of government brings new opportunities. Candesic Managing Partner Dr Leonid Shapiro and Special Advisor Dr Joe Taylor look…Candesic reviews the outlook of the market (demand drivers and tariff evolutions)
27 August 2024Following the sale of Medneo UK to CVC DIF, a potential sale of the Medneo German business would likely attract…Cost of fixing the waiting list crisis
25 July 2024In the latest edition LaingBuisson HealthcareMarkets, Candesic Senior Partner Dr Michelle Tempest and Senior Engagement Manager Jack Zeng count the…Voluntary role
16 July 2024As the number and complexity of clinical trials rises, participants are an increasingly precious resource.In an online piece for PharmaTimes,…In conversation with Andrew Cannon
9 July 2024There is a new man at the helm of UK-based telehealth / teleradiology focused Medica Group, and he is in conversation…Labour has won the UK general election. What now?
8 July 2024It has been waiting a long time for the opportunity to govern, and the public having spoken, now is the…Food for thought
3 July 2024Some food for thought. “Miracle” weight loss drugs are hitting the headlines at the moment, but amid all the celebrity…General election 2024: the health and care manifesto pledges
19 June 2024With a UK general election looming on Thursday, July 4, and the party campaigns now in full swing to win…EU ophthalmology attracts investors
12 June 2024In the latest edition of LaingBuisson HealthcareMarkets, Candesic Senior Partner Marc Kitten investigates why, and looks at its growth potential…PHIN Private market update: June 2024
10 June 2024The latest data released last week from UK-based PHIN, the Private Healthcare Information Network, makes interesting reading. It shows new…